<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119413</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-30</org_study_id>
    <nct_id>NCT05119413</nct_id>
  </id_info>
  <brief_title>Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma</brief_title>
  <acronym>Kligman</acronym>
  <official_title>Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma: a Double Blind Prospective Randomzed Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which&#xD;
      is an effective anti-melanogenic compound but that has poor tolerance and numerous&#xD;
      side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a&#xD;
      very good safety profile. The objective of this study is to compare the Kligman's trio to the&#xD;
      same preparation in which hydroquinone is replaced by thiamidol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The melasma's type</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Clinical score MASI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Quality of life of patient</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>descriptive name of scale : meslascol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Melanosis</condition>
  <arm_group>
    <arm_group_label>New traitement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thiamidol, retinoid, topical steroid preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kligman's trio</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Application once a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>New trio de Kligman</intervention_name>
    <description>Once daily application in addition to the same sunscreen</description>
    <arm_group_label>New traitement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trio Kligman</intervention_name>
    <description>Once daily application in addition to the same sunscreen</description>
    <arm_group_label>Kligman's trio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  SIGNED WRITTEN CONSENT 1) Melasma clinically diagnosed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant woman&#xD;
&#xD;
          2. Other pigmentary disorder affecting the face&#xD;
&#xD;
          3. Use of systemic or topical steroids or retinoids, use of topical depigmenting agents&#xD;
             or depigmenting procedure in the month before the inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Passeron, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice, Service de Dermatologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry Passeron, phD</last_name>
    <phone>+33492036488</phone>
    <email>passeron.t@chu-nice.fr</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

